The low-molecular-weight heparin, nadroparin, inhibits tumour angiogenesis in a rodent dorsal skinfold chamber model.
BACKGROUND
Recently, low-molecular-weight heparins (LMWHs) were found to confer a survival advantage in cancer patients. The mechanism underlying this observation is unclear, but may involve inhibition of tumour angiogenesis. We aimed to examine the effects of nadroparin on tumour angiogenesis using a dorsal skinfold window chamber model in the Syrian hamster.


METHODS
AMel-3 and HAP-T1 tumours were grown in donor animals and fragments implanted in the window chambers. Animals (N=46) were treated with 200 IU of nadroparin or saline for 10 days. Repeated intravital fluorescence microscopy was performed to calculate functional microcirculatory parameters: number (N) and length (L) of microvessels, vascular area fraction (AF), and red blood cell velocity (V). Microvessel density (MVD), fractal dimension, and pericyte coverage were assessed histologically.


RESULTS
Active angiogenesis was observed in control animals, resulting in a significant increase in N, L, and AF. In nadroparin-treated animals, however, N and L did not increase whereas AF decreased significantly. Both groups showed an initial increase in V, but nadroparin treatment resulted in an earlier decrease in red blood cell velocity over time. Compared with control animals, nadroparin-treated animals showed a significantly lower MVD and fractal dimension but significantly higher pericyte coverage index (PCI).


CONCLUSIONS
Taken together, these results suggest that the LMWH nadroparin inhibits tumour angiogenesis and results in microvessel normalisation.
Debergh
I
I
Department of Surgery, University Hospital, De Pintelaan 185, Ghent, Belgium.
Van Damme
N
N
Pattyn
P
P
Peeters
M
M
Ceelen
W P
WP
D000818:Animals; D000925:Anticoagulants / Q000494:pharmacology*; D001783:Blood Flow Velocity / Q000187:drug effects; D006224:Cricetinae; D004912:Erythrocytes / Q000187:drug effects; D007124:Immunoenzyme Techniques; D008546:Melanoma, Experimental / Q000098:blood supply*; D008647:Mesocricetus; D008833:Microcirculation / Q000187:drug effects; D017762:Nadroparin / Q000494:pharmacology*; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D010190:Pancreatic Neoplasms / Q000098:blood supply*; D012878:Skin Neoplasms / Q000517:prevention & control*
D000925:Anticoagulants; D017762:Nadroparin